We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.
BLCM

Delisted

BLCM was delisted on the 1st of June, 2023.

Back to rankings

55 hedge funds and large institutions have $300M invested in Bellicum Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 55 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
55
Holders Change
+55
Holders Change %
–
% of All Funds
1.47%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
55
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$91.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$32.4M
3
PA
Perceptive Advisors
New York
+$22.4M
4
RCM
RA Capital Management
Massachusetts
+$22M
5
RG
Redmile Group
California
+$18.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$98.7M +$91.9M +428,373 New
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$33.9M +$32.4M +151,165 New
PA
3
Perceptive Advisors
New York
$24.1M +$22.4M +104,640 New
RG
4
Redmile Group
California
$17.3M +$18.5M +86,081 New
Jennison Associates
5
Jennison Associates
New York
$16.8M +$16.1M +75,111 New
JP Morgan Chase
6
JP Morgan Chase
New York
$11.5M +$10.7M +49,757 New
RCM
7
RA Capital Management
Massachusetts
$9.34M +$22M +102,640 New
Citadel Advisors
8
Citadel Advisors
Florida
$7.8M +$7.26M +33,853 New
SFM
9
Sphera Funds Management
Israel
$6.96M +$7.11M +33,151 New
PC
10
PointState Capital
New York
$5.76M +$5.36M +25,000 New
ACA
11
Avoro Capital Advisors
New York
$5.07M +$4.72M +22,000 New
EA
12
Emerald Advisers
Pennsylvania
$4.57M +$4.25M +19,820 New
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$4.42M +$4.12M +19,200 New
Adage Capital Partners
14
Adage Capital Partners
Massachusetts
$3.92M +$3.65M +17,000 New
EMFAT
15
Emerald Mutual Fund Advisers Trust
Pennsylvania
$3.85M +$3.59M +16,721 New
Morgan Stanley
16
Morgan Stanley
New York
$3.46M +$3.22M +15,027 New
Franklin Resources
17
Franklin Resources
California
$3.46M +$3.22M +15,000 New
Federated Hermes
18
Federated Hermes
Pennsylvania
$2.88M +$2.68M +12,500 New
Millennium Management
19
Millennium Management
New York
$2.47M +$2.3M +10,716 New
FCMI
20
Foresite Capital Management II
California
$2.42M +$2.25M +10,500 New
LCM
21
Laurion Capital Management
New York
$2.33M +$2.17M +10,100 New
Deutsche Bank
22
Deutsche Bank
Germany
$2.28M +$2.13M +9,909 New
UBS AM
23
UBS AM
Illinois
$2.09M +$1.95M +9,070 New
Marshall Wace
24
Marshall Wace
United Kingdom
$1.83M +$1.7M +7,935 New
Wellington Management Group
25
Wellington Management Group
Massachusetts
$1.74M +$1.62M +7,558 New
1
2 3

BLCM Hedge Fund Activity: Q4 2014 in Review

55 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2014, worth a combined $300M.

Buyers outnumbered sellers: 55 funds opened new BLCM positions and 0 closed out — a net gain of 55 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $91.9M.

  • 55 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2014, up from 0 in Q3 2014.
  • Funds reported $300M of Bellicum Pharmaceuticals, Inc. stock for Q4 2014.
  • 55 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2014 and 0 closed out, a net change of +55 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2014 was Baker Bros. Advisors, an estimated $91.9M added.

Based on aggregated 13F filings for Q4 2014.